People on the Move
Ophthotech
Ophthotech, a biopharma company developing treatments for eye diseases, especially age-related macular degeneration (AMD), has replaced its Executive VP, Chief Financial and Business Officer and Treasurer with a hire from Merck & Co. Michael Atieh will replace Bruce Peacock when he vacates the three roles tomorrow.
Atieh spent most of his pharmaceutical career at Merck and Co., where he was variously Senior Vice President, Merck Medco Managed Care; Vice President, US Human Health; Vice President, Public Affairs; Vice President, Government Relations; and Treasurer.
He also serves on the Board of Directors of Theravance Biopharma where he is a member of the Audit Committee. He was Executive Chairman of Eyetech from 2009 until the company was acquired by Valeant Pharmaceuticals in 2012.